Activated Protein C Resistance (APCR) and Placental Fibrin Deposition

Placenta

Volumn 29, Issue 9, 2008, Pages 833-837

  Sedano, S ^a   Gaffney, G ^b   Mortimer, G ^b   Lyons, M ^b   Cleary, B ^b   Murray, M ^b   Maher, M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Activated protein C resistance (APCR); Placental fibrin deposition; Placental histological abnormalities; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FIBRIN DEPOSITION; GESTATIONAL AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAUTERINE GROWTH RETARDATION; MUTATIONAL ANALYSIS; PLACENTA; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL;

ACTIVATED PROTEIN C RESISTANCE; FEMALE; FIBRIN; HUMANS; PLACENTA; PREGNANCY; THROMBOPHILIA;

EID: 50049130149     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2008.06.012     Document Type: Article

References (43)

1. Walker F.J., and Fay P.J. Regulation of blood coagulation by the protein C system. Faseb J 6 8 (1992) 2561-2567
2. Harris J.M., and Abramson N. Evaluation of recurrent thrombosis and hypercoagulability. Am Fam Physician 56 6 (1997) 1591-1596 1601-2
3. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 86 1 (2001) 395-403
4. Naeye R.L. Placental infarction leading to fetal or neonatal death. A prospective study. Obstet Gynecol 50 5 (1977) 583-588
5. Kitzmiller J.L., and Benirschke K. Immunofluorescent study of placental bed vessels in pre-eclampsia of pregnancy. Am J Obstet Gynecol 115 2 (1973) 248-251
6. Simpson E.L., Lawrenson R.A., Nightingale A.L., and Farmer R.D. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. Bjog 108 1 (2001) 56-60
7. Salafia C.M., Minior V.K., Pezzullo J.C., Popek E.J., Rosenkrantz T.S., and Vintzileos A.M. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am J Obstet Gynecol 173 4 (1995) 1049-1057
8. Goddijn-Wessel T.A.W., Wouters M.G.A.J., and Molen E.F.V.D. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gumecol Reprod Biol 66 (1996) 23-29
9. Gruenwald P. Chronic fetal distress and placental insufficiency. Biol Neonat 33 (1963) 215-265
10. Redline R.W., and Pappin A. Fetal thrombotic vasculopathy: the clinical significance of extensive avascular villi. Hum Pathol 26 1 (1995) 80-85
11. Sander C.M., Gilliland D., Flynn M.A., and Swart-Hills L.A. Risk factors for recurrence of hemorrhagic endovasculitis of the placenta. Obstet Gynecol 89 4 (1997) 569-576
12. Huang S.T., Vo K.C., Lyell D.J., Faessen G.H., Tulac S., Tibshirani R., et al. Developmental response to hypoxia. Faseb J 18 12 (2004) 1348-1365
13. Thaete L.G., Dewey E.R., and Neerhof M.G. Endothelin and the regulation of uterine and placental perfusion in hypoxia-induced fetal growth restriction. J Soc Gynecol Investig 11 1 (2004) 16-21
14. Wolf C.E., Haubelt H., Pauer H.U., Hinney B., Krome-Cesar C., Legler T.J., et al. Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor. Pathophysiol Haemost Thromb 33 3 (2003) 134-137
15. Lunghi B., Castoldi E., Mingozzi F., and Bernardi F. A new factor V gene polymorphism (His 1254 Arg) present in subjects of African origin mimics the R2 polymorphism (His 1299 Arg). Blood 91 1 (1998) 364-365
16. Williamson D., Brown K., Luddington R., Baglin C., and Baglin T. Factor V Cambridge: a new mutation (Arg306 → Thr) associated with resistance to activated protein C. Blood 91 4 (1998) 1140-1144
17. Dordevic V., Rakicevic L., Spasic M., Mikovic D., Kovac M., and Radojkovic D. [Factor V Leiden, FII G20210A, MTHFR C677T mutations as risk factors for venous thrombosis during pregnancy and puerperium]. Vojnosanit Pregl 62 3 (2005) 201-205
18. Axelsson F., and Rosen S. APC resistance. Chromogenix AB. Product Monograph (1997) 1997 Version 2.1
19. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., and Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332 14 (1995) 912-917
20. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 10 (1996) 3698-3703
21. Peng F., Labelle L.A., Rainey B.J., and Tsongalis G.J. Single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene are common in US Caucasian and Hispanic American populations. Int J Mol Med 8 5 (2001) 509-511
22. Lendrum A.C., Fraser D.S., Slidders W., and Henderson R. Studies on the character and staining of fibrin. J Clin Pathol 15 (1962) 401-413
23. Kraus FT, Redline RW, Gersell DJ, Nelson DM, Dicke JM. Atlas of nontumor pathology 3. American Registry of Pathology; 2004.
24. Redline R.W. Thrombophilla and placental pathology. Clin Obstet Gynecol 49 4 (2006) 885-894
25. Redline R., Boyd T., Campbell V., Hyde S., Kaplan C., Khong T., et al. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Devel Pathol 7 (2004) 237-249
26. Rai R.S., Regan L., Chitolie A., Donald J.G., and Cohen H. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol 103 8 (1996) 842-844
27. Rai R., Regan L., Hadley E., Dave M., and Cohen H. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol 92 2 (1996) 489-490
28. Brenner B., Mandel H., Lanir N., Younis J., Rothbart H., Ohel G., et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 97 3 (1997) 551-554
29. Tal J., Schliamser L.M., Leibovitz Z., Ohel G., and Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 14 6 (1999) 1624-1627
30. Brenner B. Haemostatic changes in pregnancy. Thromb Res 114 5-6 (2004) 409-414
31. Bane A.L., and Gillan J.E. Massive perivillous fibrinoid causing recurrent placental failure. Br J Obstet Gynaecol 110 (2003) 292
32. Kanfer A., Bruch J.F., Nguyen G., He C.J., Delarue F., Flahault A., et al. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest 74 1 (1996) 253-258
33. Livingston J.C., Maxwell B.D., and Sibai B.M. Chronic hypertension in pregnancy. Minerva Ginecol 55 1 (2003) 1-13
34. Sheppard B.L., and Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth retardation. Semin Thromb Hemost 25 5 (1999) 443-446
35. Bremme K., and Blomback M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia. Gynecol Obstet Invest 41 1 (1996) 20-26
36. Kupferminc M.J. Thrombophilia and preeclampsia: the evidence so far. Clin Obstet Gynecol 48 2 (2005) 406-415
37. Many A., Schreiber L., Rosner S., Lessing J.B., Eldor A., and Kupferminc M.J. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 98 6 (2001) 1041-1044
38. Vern T.Z., Alles A.J., Kowal-Vern A., Longtine J., and Roberts D.J. Frequency of factor V (Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol 31 9 (2000) 1036-1043
39. Robertson L., Langhorne P., Twaddle S., Clark P., Lowe G.D., Walker I.D., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2006) 171-196
40. Dizon-Townson D., Miller C., Sibai B., Spong C.Y., Thom E., Wendel G.J., et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 106 (2005) 517-524
41. Vaughan J, Power C, Nolan C, McCarthy D, Shirley I. The incidence of factor V Leiden in a normal Irish population and its relationship to the laboratory diagnosis of APC resistance. Thromb Haemost 1999; Apr;81(4):661-663.
42. Livingstone W.J., Keenan C., White B., Mynett-Johnson L., Lawler M., Mayne P., et al. Prevalence of the factor VR506Q mutation in two Irish control populations: use of a novel nested polymerase chain reaction approach. Br J Haematol 111 2 (2000) 559-561
43. Botto L.D., and Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151 9 (2000) 862-877